2017-03-22 16:15:29 CET

2017-03-22 16:15:29 CET


REGULATED INFORMATION

Finnish English
Orion - Other information disclosed according to the rules of the Exchange

Orion Corporation: Organising meeting of the Board of Directors


ORION CORPORATION         STOCK EXCHANGE RELEASE 22 MARCH 2017 at 5.15 P.M.
EET

Orion Corporation: Organising meeting of the Board of Directors

In its organising meeting, the Board of Directors of Orion Corporation, which
was elected today by the Annual General Meeting of the Shareholders, has elected
Timo Maasilta as Vice Chairman.

The compositions of the Board committees were decided to be as follows:

Remuneration Committee:
Heikki Westerlund, Chairman
Timo Maasilta
Mikael Silvennoinen

Audit Committee:
Mikael Silvennoinen, Chairman
Ari Lehtoranta
Hilpi Rautelin
Eija Ronkainen

R&D Committee:
Sirpa Jalkanen, Chairman
Ari Lehtoranta
Timo Maasilta
Hilpi Rautelin
Eija Ronkainen
Mikael Silvennoinen
Heikki Westerlund


The members to the Nomination Committee were elected on 7 September 2016 as
stated in the stock exchange release on the same day.

The Board of Directors has assessed the independence of its members and
concluded that all the members are independent of the company and its
significant shareholders.



Orion Corporation



 Timo Lappalainen    Olli Huotari
 President and CEO   SVP, Corporate Functions





Contact person:
Olli Huotari, SVP, Corporate Functions, Secretary of the Board of Directors,
phone +358 50 966 3054


Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish pharmaceutical company - a builder of
well-being. Orion develops, manufactures and markets human and veterinary
pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The
company is continuously developing new drugs and treatment methods. The core
therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS)
disorders, oncology and respiratory for which Orion developes inhaled Easyhaler®
pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the
company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq
Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.

[]